This pathological pathway may be particularly important in COVID-19, since ACE2 dysregulation may explain the higher mortality among elderly and overweight cardiovascular patients, implicating circulating ACE2 as a biomarker of COVID-19 mortality. Here, ACE2 is linked to COVID-19.